Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

The role of p53 in apoptosis.

Amaral JD, Xavier JM, Steer CJ, Rodrigues CM.

Discov Med. 2010 Feb;9(45):145-52. Review.

2.

p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis.

Amaral JD, Castro RE, Steer CJ, Rodrigues CM.

Trends Mol Med. 2009 Nov;15(11):531-41. doi: 10.1016/j.molmed.2009.09.005. Epub 2009 Oct 12. Review.

PMID:
19822456
3.

Targeting the p53 pathway of apoptosis.

Amaral JD, Xavier JM, Steer CJ, Rodrigues CM.

Curr Pharm Des. 2010;16(22):2493-503. Review.

PMID:
20500145
4.

Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors.

Solá S, Amaral JD, Aranha MM, Steer CJ, Rodrigues CM.

Curr Med Chem. 2006;13(25):3039-51. Review.

PMID:
17073645
5.

Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes.

Solá S, Castro RE, Kren BT, Steer CJ, Rodrigues CM.

Biochemistry. 2004 Jul 6;43(26):8429-38.

PMID:
15222754
6.

The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent.

Rodrigues CM, Steer CJ.

Expert Opin Investig Drugs. 2001 Jul;10(7):1243-53. Review.

PMID:
11772248
7.

Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation.

Park IH, Kim MK, Kim SU.

Biochem Biophys Res Commun. 2008 Dec 26;377(4):1025-30. doi: 10.1016/j.bbrc.2008.06.014. Epub 2008 Jun 17.

PMID:
18558085
8.
9.

The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death.

Chari NS, Pinaire NL, Thorpe L, Medeiros LJ, Routbort MJ, McDonnell TJ.

Apoptosis. 2009 Apr;14(4):336-47. doi: 10.1007/s10495-009-0327-9. Review.

PMID:
19229632
10.

Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes.

Castro RE, Amaral JD, Solá S, Kren BT, Steer CJ, Rodrigues CM.

Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G327-34. Epub 2007 Apr 12.

11.

Activation of p53 by specific agents in potential cancer therapy.

Ho JW, Song JZ, Leung YK.

Curr Med Chem Anticancer Agents. 2005 Mar;5(2):131-5. Review.

PMID:
15777220
12.

The role of p53-target genes in human cancer.

Tokino T, Nakamura Y.

Crit Rev Oncol Hematol. 2000 Jan;33(1):1-6. Review.

PMID:
10714958
13.

p53: fighting cancer.

Selivanova G.

Curr Cancer Drug Targets. 2004 Aug;4(5):385-402. Review.

PMID:
15320716
14.

The dual role of mutant p53 protein in chemosensitivity of human cancers.

Mueller H, Eppenberger U.

Anticancer Res. 1996 Nov-Dec;16(6B):3845-8. Review.

PMID:
9042268
15.
16.

p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis.

Amaral JD, Castro RE, Solá S, Steer CJ, Rodrigues CM.

J Biol Chem. 2007 Nov 23;282(47):34250-9. Epub 2007 Sep 19.

17.

Therapeutic targeting of the p53 tumor suppressor gene.

Beaudry GA, Bertelsen AH, Sherman MI.

Curr Opin Biotechnol. 1996 Dec;7(6):592-600. Review.

PMID:
8939636
18.

Does p53 status influence tumor response to anticancer therapies?

Pirollo KF, Bouker KB, Chang EH.

Anticancer Drugs. 2000 Jul;11(6):419-32. Review.

PMID:
11001382
19.

The genetics of the p53 pathway, apoptosis and cancer therapy.

Vazquez A, Bond EE, Levine AJ, Bond GL.

Nat Rev Drug Discov. 2008 Dec;7(12):979-87. doi: 10.1038/nrd2656. Review.

PMID:
19043449
20.

Reactivation of mutant p53: a new strategy for cancer therapy.

Selivanova G, Kawasaki T, Ryabchenko L, Wiman KG.

Semin Cancer Biol. 1998;8(5):369-78. Review.

PMID:
10101802

Supplemental Content

Support Center